Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 3/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.43 |
| ▸ | HTR2C | P28335 | 6/20 | 0.42 |
| ▸ | HTR2B | P41595 | 4/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20700474 | 1.00 | DRD1 (0.60) | DRD1KEAP1ADRA2AADRA2BADRA2C | |
| SCHEMBL20700131 | 0.92 | DRD1 (0.51) | DRD1KEAP1ADRA2AADRA2BADRA2C | |
| SCHEMBL15319521 | 0.84 | DRD1 (0.42) | DRD1KEAP1HTR2CHTR2BSLC6A2 | |
| SCHEMBL298490 | 0.84 | DRD1 (0.45) | DRD1ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL19812912 | 0.81 | DRD1 (0.60) | DRD1KEAP1ADRA2AADRA2BADRA2C | |
| SCHEMBL19812865 | 0.81 | DRD1 (0.60) | DRD1KEAP1ADRA2AADRA2BADRA2C | |
| SCHEMBL19812863 | 0.81 | DRD1 (0.60) | DRD1KEAP1ADRA2AADRA2BADRA2C | |
| SCHEMBL19813036 | 0.81 | DRD1 (0.60) | DRD1KEAP1ADRA2AADRA2BADRA2C | |
| SCHEMBL19813012 | 0.81 | DRD1 (0.60) | DRD1KEAP1ADRA2AADRA2BADRA2C | |
| SCHEMBL19813088 | 0.81 | DRD1 (0.60) | DRD1KEAP1ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388558-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250304546-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4593954-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PGI Drug Discovery LLC (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250243173-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250236602-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250129035-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2024073383-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PGI DRUG DISCOVERY LLC (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129035-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PMP22, INA, SLC18A2 | DRD1 1222/4885KEAP1 469/4885ADRA2A 1680/4885 |
| US-20250236602-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PMP22, INA, SLC18A2 | DRD1 1222/4885KEAP1 469/4885ADRA2A 1680/4885 |
| US-20250304546-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PMP22, INA, SLC18A2 | DRD1 1222/4885KEAP1 469/4885ADRA2A 1680/4885 |
| US-20250243173-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PMP22, INA, SLC18A2 | DRD1 1222/4885KEAP1 469/4885ADRA2A 1680/4885 |
| US-20250388558-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | GRIN2C, SLC6A1, CLIC1 | DRD1 527/4885KEAP1 1281/4885ADRA2A 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.